Energesis Pharmaceuticals, Inc.
PrivateLast Round
Grant
Sep 30, 2021
Total Funding Raised
$4.53M
Company Overview
Energesis Pharmaceuticals, Inc. operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Grant round in September 2021.
Energesis Pharmaceuticals, Inc. is a biotechnology company that develops therapeutic drugs for the treatment of obesity, diabetes, and related metabolic diseases by leveraging brown adipose tissue biology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Energesis Pharmaceuticals, Inc. Comparables
Compare Energesis Pharmaceuticals, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Brite Therapeutics | 88% | |
| Atrogi AB | 84% | |
| Eolo Pharma | 83% |
For institutional investors. Book with your work email.
Energesis Pharmaceuticals, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 30, 2021 | ||||
| Grant | Sep 1, 2021 | ||||
| Grant | Sep 30, 2019 | ||||
| Grant | Sep 30, 2018 | ||||
| Grant | Sep 30, 2015 | ||||
Grant | May 27, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Energesis Pharmaceuticals, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Massachusetts Life Sciences Center | Grant |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| MassChallenge Israel | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2025
Grew 100% QoQ from 3 to 6 employees.
- Sep 30, 2021
$982K grant from National Institute of Diabetes and Digestive and Kidney Diseases
For institutional investors. Book with your work email.
Energesis Pharmaceuticals, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Energesis Pharmaceuticals, Inc.'s valuation, stock price, and market status.
Is Energesis Pharmaceuticals, Inc. a public or private company?
Energesis Pharmaceuticals, Inc. is a private company.
What is the current stock price of Energesis Pharmaceuticals, Inc.?
Energesis Pharmaceuticals, Inc. is a private company, so its shares have no public market price. Caplight tracks Energesis Pharmaceuticals, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Energesis Pharmaceuticals, Inc. worth (valuation)?
Valuation information for Energesis Pharmaceuticals, Inc. is not publicly available.
Can I buy Energesis Pharmaceuticals, Inc. stock?
Energesis Pharmaceuticals, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Energesis Pharmaceuticals, Inc.'s last funding round?
Energesis Pharmaceuticals, Inc.'s most recent funding round was Grant on September 30, 2021.
Who are the main investors in Energesis Pharmaceuticals, Inc.?
Key investors in Energesis Pharmaceuticals, Inc. include Massachusetts Life Sciences Center, National Institute of Diabetes and Digestive and Kidney Diseases, MassChallenge Israel.
Will Energesis Pharmaceuticals, Inc. IPO soon?
No public IPO plans have been announced for Energesis Pharmaceuticals, Inc..
How can I track Energesis Pharmaceuticals, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Energesis Pharmaceuticals, Inc.'s shares on secondary markets.